Insight Molecular Diagnostics to showcase GraftAssure at American Transplant Congress
PUBT · 06/09 20:06
Share
Listen to the news
- Insight Molecular Diagnostics will highlight its GraftAssure transplant rejection monitoring technology at the American Transplant Congress in Boston, June 20-24.
- A private reception with transplant physicians and lab directors is scheduled during the meeting to discuss in-house dd-cfDNA testing.
- Third-party late-breaking head-to-head data on GraftAssureIQ versus a commercial centralized test is set for presentation June 23.
- Grant winners for an iMDx-ASTS study on in-house versus centralized testing economics will be announced at the conference.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insight Molecular Diagnostics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606091605PRIMZONEFULLFEED9734398) on June 09, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved